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To the Editor
Coronavirus disease 2019 (COVID-19), caused 
by the novel severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), is an exponentially 
spreading pandemic with more than 36 million 
confirmed cases and over one million deaths 
worldwide, all within ten months of its first case 
in Wuhan, China [1]. The brunt of the infection 
affects the respiratory system and may range in 
presentation from an asymptomatic infection 
to severe acute respiratory distress syndrome 
(ARDS). Although more than 25 million cases 
have been reported to have recovered globally 
[2], an alarming upcoming trend is that of the 
long-term sequelae of COVID-19, the most dev-
astating of which is pulmonary fibrosis. Referral 
for up to 10–15% of non-critically ill moderate 
to severe COVID-19 patients is sought in view of 
varying degrees of fibrotic change in the lungs 
in the authors’ growing experience. Irrespective 
of the underlying etiology, pulmonary fibrosis 
notoriously jeopardizes the patient’s functional 
capacity, confers chronic respiratory insuffi-
ciency, and consequently, compromises quality 
of life. Due to dearth of conclusive data, it may 
not be presently possible to compute the actual 
prevalence of COVID-19 lung fibrosis. However, 
given the enormity of the pandemic and its pre-
dominant and wide range of effects on the lungs, 
a significant burden of post-COVID-19 pulmonary 
fibrosis is anticipated [3]. Therefore, long-term 
follow-up studies will be desperately needed to 
address this issue.
The pathogenesis of pulmonary fibrosis in-
volves alveolar epithelial damage triggered by ge-
netic predisposition, unchecked chronic inflam-
mation, viral infections, or ARDS. This happens 
due to the overexpression of pro-inflammatory 
cytokines (i.e. tumor necrosis factor-alpha, inter-
leukins), proliferation and persistence of pro-fi-
broblastic cells and mediators (i.e. fibroblasts, 
transforming growth factor-beta, fibroblast growth 
factor, platelet derived growth factor), and resul-
tant activation of the profibrotic pathway. Excess 
collagen and extracellular matrix replace normal 
lung tissue and produce architectural distortion 
typical of interstitial pulmonary fibrosis. Recent 
reports suggest that these mediators are likely 
implicated in COVID-19 lung fibrosis as well, as 
suggested by their increased serum levels in these 
patients [4–6].
The typical sequence of events in COVID-19 pa-
tients developing pulmonary fibrosis consists of an 
upper respiratory viral prodrome, atypical pneu-
monia, and ARDS culminating in fibrosis. Fibrosis 
may begin during or after the acute infectious 
episode and is more likely to develop in patients 
with a prolonged severe illness due to a cytokine 
storm, in those with pre-existing lung conditions, 
and in the elderly. No definitive profibrotic mech-
anisms are known in COVID-19 patients; howev-
er, pulmonary fibrosis in fatal COVID-19 cases 
characteristically shows the histological picture 
of diffuse alveolar damage and microthrombo-
sis. Other proposed mechanisms driving fibrosis 
in these patients include a cytokine storm-related 
hyperimmune response triggered by the SARS-
CoV-2 antigen, severe acute lung injury, fibrosing 
organizing pneumonia, and drug induced- and/or 
artificial ventilation-induced lung damage. It may 
not always be possible to identify which mech-
anism is at work in a particular patient. Further, 
even after the virus gets cleared in patients who 
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have recovered from COVID-19, it does not neces-
sarily mean that fibrosis may not ensue. However, 
COVID-19-related lung fibrosis is supposedly not 
a progressive fibrosing interstitial lung disease 
(PF-ILD).
In the landmark placebo-controlled INBUILD 
trial, nintedanib was administered to patients 
who had progressive pulmonary fibrosis due 
to a wide variety of interstitial lung diseases 
(ILDs). The drug intervention was associated with 
a reduction in FVC decline (about 60%) thereby 
concluding that nintedanib appears to inhibit 
fibrogenesis across a broad range of pulmonary 
diseases [7]. Somewhat similar effects were ob-
served with pirfenidone in another phase-2 ran-
domized controlled trial [8]. An autopsy study 
of ARDS patients noted that longer the disease 
duration, greater were the chances of fibrosis 
[9]. Such patients may benefit from antifibrotic 
drugs if introduced early in the disease course 
before the need for mechanical ventilation emerg-
es. These studies potentially imply that the early 
use of antifibrotics in COVID-19 lung fibrosis may 
possibly reduce immune-mediated fibrotic lung 
changes. However, other aspects of lung damage 
like inflammation and thrombosis must also be 
optimally addressed to maximize the potential 
benefit.
In light of these facts, the question that is 
currently puzzling clinicians around the world is 
whether antifibrotics indicated for other PF-ILDs 
would be of any benefit in COVID-19 patients 
developing lung fibrosis. Available anti-fibrotic 
medications like pirfenidone and nintedanib 
approved for use in PF-ILDs like idiopathic pul-
monary fibrosis (IPF) and scleroderma-interstitial 
lung disease have broad anti-fibrotic activity 
irrespective of the underlying etiology. Impor-
tantly, the similar cytokine profiles in IPF and 
COVID-19 possibly suggest similar pathogenic 
mechanisms of lung fibrosis in both diseases, thus 
implying the likely utility of antifibrotics used in 
IPF for COVID-19 patients also, in whom they may 
be expected to prevent occurrence and/or progres-
sion of fibrosis. Therefore, it would be interesting 
to explore their full potential role, if any, in such 
patients to fulfil the urgent but largely unmet need 
for such therapies. Nevertheless, their use must 
not be outside of experimental studies, and the 
optimal timing of initiation, dosage, and duration 
of treatment must be determined.
No evidence currently exists to support empir-
ical off-label use of antifibrotics in COVID-19 pa-
tients. Thus, well-designed, prospective, random-
ized clinical trials of these drugs in this group of 
patients are warranted. Until conclusive evidence 
builds up, these patients may probably best be 
offered aggressive pulmonary rehabilitation, 
possibly an extended course of low dose steroids 
on a case-by-case basis, and a trial of antifibrotic 
agents within a study protocol with periodic 
assessment of lung function and chest imaging. 
It is also likely that quite a few of these patients 
may have their lung changes resolved with time, 
possibly over a period of months. Such trends 
were also evident in previous coronavirus out-
breaks where spontaneous but gradual resolution 
of fibrotic sequelae was observed [10, 11].
To conclude, limiting the development of 
post-COVID-19 lung fibrosis is expected to be 
a challenge in view of the blistering disease 
course and the ongoing search for effective an-
tivirals, anti-inflammatory agents, and immu-
nomodulatory therapies. Even a small degree of 
fibrosis in these patients, especially in the elderly 
who may quite commonly have other preexisting 
respiratory comorbidities, may be sufficient to 
significantly compromise their lung function and 
quality of life. Insightful evidence on therapeu-
tic options for the treatment of this dangerous 
disease may bring about a landmark change in 
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